AMGN vs MRK
Amgen and Merck & Co., both Healthcare
Merck & Co. is the larger company at $281B against $182B. On trailing earnings AMGN is the cheaper of the two at a P/E of 25.8 against 115.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year MRK returned +83% against +54% for AMGN. The RyuScore puts MRK ahead, 78 against 66 out of 100.
| Figure | AMGN | MRK |
|---|---|---|
| Last close | $415 | $146 |
| Market cap | $182B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 25.8 | 115.5 |
| Dividend yield | 2.4% | 2.3% |
| 1-year return | +54% | +83% |
| 5-year return | +122% | +132% |
| RyuScoresector-relative, 1–10 | 66/100 | 78/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.